Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Reveals Path To $3.31 Billion By 2030

The chronic inflammatory demyelinating polyneuropathy (CIDP) market is poised for significant expansion in the coming years, driven by advancements in treatment and growing patient awareness. As the medical community continues to innovate, the market outlook suggests promising opportunities for enhanced therapies and improved patient care.

Anticipated Market Growth and Size of the CIDP Market
The CIDP market is projected to reach a value of $3.32 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.8%. This upward trajectory is fueled by several factors including the development of new targeted immunotherapies, a stronger emphasis on reducing the side effects of treatments, and the expansion of remote patient monitoring technologies. Additionally, there is an increasing demand for therapies that provide sustained remission and a rising level of investment in research focused on rare diseases. Key trends shaping this market encompass the growing use of intravenous immunoglobulin (IVIG) as a primary treatment, the adoption of personalized therapy approaches, the integration of sophisticated diagnostic tools, expansion of home-based treatment models, and a heightened focus on managing the disease over the long term.

The chronic inflammatory demyelinating polyneuropathy (cidp) market size has grown strongly in recent years. It will grow from $2.27 billion in 2025 to $2.46 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to improved awareness of rare autoimmune neuropathies, wider availability of ivig therapies, advancements in electrodiagnostic testing, increased specialist neurology care, better recognition of cidp subtypes.

Download a free sample of the chronic inflammatory demyelinating polyneuropathy (cidp) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Contributing to Growth in the CIDP Market
Innovations in targeted immunotherapies are playing a vital role in driving market growth. These therapies aim to improve treatment precision and reduce adverse effects, enhancing the overall patient experience.
Moreover, the increasing availability and acceptance of remote patient monitoring are revolutionizing how CIDP is managed. Remote care allows for continuous observation without frequent hospital visits, improving convenience and treatment adherence.

Leading Companies Influencing the CIDP Market Landscape
The CIDP market is dominated by several prominent pharmaceutical and biotechnology firms, including Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, and HanAll Pharma.
A notable recent development occurred in November 2024, when China-based Zai Lab Limited partnered with Netherlands-based argenx SE to introduce VYVGART Hytrulo, the first approved subcutaneous injection for CIDP in China. This collaboration aims to offer a convenient and effective treatment option that addresses unmet medical needs and improves patient outcomes.

View the full chronic inflammatory demyelinating polyneuropathy (cidp) market report:
https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Enhancing Treatment Approaches in the CIDP Market
Many leading companies are focusing on improving intravenous immunoglobulin (IVIG) therapies to increase their effectiveness and safety profiles. IVIG therapy involves administering concentrated antibodies from healthy donors, which helps regulate the immune system and decrease inflammation associated with autoimmune conditions like CIDP.
For example, in January 2024, Takeda Pharmaceutical Company Limited received FDA approval for GAMMAGARD LIQUID, an IVIG treatment for adults with CIDP. This approval allows its use as an induction therapy with an initial dose followed by maintenance doses, supporting sustained disease management and improved neuromuscular function.

Detailed Market Segmentation of the Global CIDP Market
The CIDP market is divided into several key segments to provide a comprehensive understanding:
1) Treatment types including Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, and Other Treatments
2) Routes of administration such as Intravenous, Oral, and other methods
3) Diagnostic techniques including Electrodiagnostic Testing, Nerve Conduction Studies, Electromyography (EMG), Spinal Fluid Analysis, and other methods
4) Distribution channels like Hospitals, Pharmacies, Online Pharmacies, and Specialty Clinics
5) End users including Hospitals, Research Institutions, and Homecare settings

Further subcategories classify treatments in more detail:
For Intravenous Immunoglobulin (IVIG), there are Standard and High-Dose therapies;
Corticosteroids are split into Oral and Intravenous types;
Plasmapheresis is segmented into Single-Exchange and Multiple-Exchange procedures;
Physiotherapy includes Muscle Strengthening Exercises and Balance and Coordination Therapy;
Other treatments cover Immunosuppressive Agents and Monoclonal Antibodies.

New additions to our 2026 reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.